Literature DB >> 28359785

Optimum dosing of ipilimumab in melanoma: too little, too late?

Alexander M Menzies1, Georgina V Long2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28359785     DOI: 10.1016/S1470-2045(17)30228-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies.

Authors:  Manish A Shah; Anghel Adrian Udrea; Igor Bondarenko; Was Mansoor; Raquel Guardeño Sánchez; Tomasz Sarosiek; Silvia Bozzarelli; Michael Schenker; Carlos Gomez-Martin; Carys Morgan; Mustafa Özgüroğlu; Joanna Pikiel; Haralabos P Kalofonos; Elzbieta Wojcik; Tomas Buchler; Daniel Swinson; Irfan Cicin; Mano Joseph; Ihor Vynnychenko; Alexander Valerievich Luft; Peter C Enzinger; Tomas Salek; Christos Papandreou; Christophe Tournigand; Evaristo Maiello; Ran Wei; David Ferry; Ling Gao; Joana M Oliveira; Jaffer A Ajani
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

2.  Post-marketing dosing changes in the label of biologicals.

Authors:  Lotte A Minnema; Thijs J Giezen; Helga Gardarsdottir; Toine C G Egberts; Hubert G M Leufkens; Aukje K Mantel-Teeuwisse
Journal:  Br J Clin Pharmacol       Date:  2019-02-16       Impact factor: 4.335

Review 3.  Master protocols in immuno-oncology: do novel drugs deserve novel designs?

Authors:  Luca Mazzarella; Stefania Morganti; Antonio Marra; Dario Trapani; Giulia Tini; Piergiuseppe Pelicci; Giuseppe Curigliano
Journal:  J Immunother Cancer       Date:  2020-03       Impact factor: 13.751

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.